TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3894101

Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) in group A
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Domperidone (DOM) in group B
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo in group A
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 17
Study: 30089075

Group type: COMPARATOR
Intervention: Placebo group (no prenatal or postpartum vitamin D supplementation)
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Prenatal 4200 IU group
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Prenatal 16,800 IU group
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Prenatal 28,000 IU group
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Prenatal and postpartum 28,000 IU group
Number of subjects: 1164
Study: 28399909

Group type: EXPERIMENTAL
Intervention: MyPlan mobile app (experimental intervention)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Safety plan on paper (Treatment as Usual, control)
Number of subjects: 546
Study: 26263592

Group type: EXPERIMENTAL
Intervention: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine
Number of subjects: 3706

Group type: EXPERIMENTAL
Intervention: Enhanced oral health promotion program with toothpaste containing 1,450 ppm F‐ and 1.5% arginine in cooperative schools
Number of subjects: 3706

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3706
Study: 23857539

Group type: EXPERIMENTAL
Intervention: 200‐microgram misoprostol vaginal insert
Number of subjects: 1358

Group type: COMPARATOR
Intervention: 10‐mg dinoprostone vaginal insert
Number of subjects: 1358
Study: 21092829

Group type: EXPERIMENTAL
Intervention: Know & Go! slide presentation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Know & Go! program
Number of subjects: 64
Study: 17419779

Group type: EXPERIMENTAL
Intervention: Evidence-based practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reflective practice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchy of evidence
Number of subjects: 0
Study: 16046015

Group type: EXPERIMENTAL
Intervention: Amiodarone 450 mg IV bolus
Number of subjects: 100

Group type: COMPARATOR
Intervention: Digoxin 0.6 mg IV bolus
Number of subjects: 100
Study: 12819556

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Estrogen-Only Replacement Therapy (ERT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 10494188

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with hematopoietic blood stem cell support
Number of subjects: 0
Study: 8889439

Group type: EXPERIMENTAL
Intervention: Local, intra-arterial infusion of insulin (0.3 mU dL-1 forearm volume min-1 for 180 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Local, intra-arterial infusion of insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined infusion of insulin and glucose (5%, 0.2 mL dL-1 min-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study: 1894759

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (120 mg, single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg, twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 6403716

Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 89
Study: 30502785

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Interferon alfa
Number of subjects: 1473

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1473
Study: 27413125

Group type: EXPERIMENTAL
Intervention: Glycomacropeptide medical foods (GMP‐MFs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amino acid medical foods (AA‐MFs)
Number of subjects: 30
Study: 25078929

Group type: EXPERIMENTAL
Intervention: Semirigid fiberglass (SRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plaster of Paris (POP)
Number of subjects: 30
Study: 23895557

Group type: EXPERIMENTAL
Intervention: Low-dose ethanol (target BrAC = 40 mg%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High-dose ethanol (target BrAC = 100 mg%)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 21066889

Group type: EXPERIMENTAL
Intervention: Zhikang Granule (ZKG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 45
Study: 18455536

Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy surgery
Number of subjects: 301
Study: 16552630

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 2408

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 2408

Group type: COMPARATOR
Intervention: sulfonylurea
Number of subjects: 2408
Study: 15182402

Group type: EXPERIMENTAL
Intervention: Strong soup with red pepper
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Strong capsules with red pepper
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moderate soup with red pepper
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo soup
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 16
Study: 11228175

Group type: EXPERIMENTAL
Intervention: Coadministration of ketoconazole (keto) with cyclosporine (CsA)
Number of subjects: 100
Study: 9306481

Group type: EXPERIMENTAL
Intervention: DTaP/PRP‐T combined vaccine
Number of subjects: 485
Study: 8457525

Group type: EXPERIMENTAL
Intervention: 25 g 13C‐labelled erythritol
Number of subjects: 6

Group type: COMPARATOR
Intervention: 25 g 13C‐labelled glucose
Number of subjects: 6

Group type: COMPARATOR
Intervention: 25 g 13C‐labelled lactitol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In vitro H2 production by faecal flora with erythritol
Number of subjects: 6
Study: 3315583

Group type: EXPERIMENTAL
Intervention: APSAC (30U intravenously)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Streptokinase (250,000U intracoronary)
Number of subjects: 85
Study: 25742062

Group type: EXPERIMENTAL
Intervention: Systematic medication review by a clinical pharmacist and clinical pharmacologist
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual medication routine (control)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Systematic medication review
Number of subjects: 108
Study: 27117703

Group type: EXPERIMENTAL
Intervention: Complex behavioural change intervention combining motivational interviewing and access to a habit formation mobile application.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control arm (details not specified).
Number of subjects: 264
Study: 24078198

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 23165582

Group type: EXPERIMENTAL
Intervention: Strategy based on changes in dietary vitamin K intake
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional dose adjustment of oral anticoagulants
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Patients achieving oral anticoagulation stability (n = 23)
Number of subjects: 132
Study: 20679166

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (IN‐MMAD) 0.2 mg/kg (max 10 mg)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Rectal diazepam (RD) 0.3 to 0.5 mg/kg (max 20 mg)
Number of subjects: 358
Study: 18728590

Group type: EXPERIMENTAL
Intervention: Radiofrequency thermorhizotomy (RF-TR)
Number of subjects: 100
Study: 16463826

Group type: EXPERIMENTAL
Intervention: Prolonged cerebral ischaemia (PBO2 decrease below 1.1 kPa for at least 30 minutes) in 3 patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Brief ICA clipping (maximum duration of 16 minutes) in 11 patients
Number of subjects: 14
Study: 12427785

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (Proviva) administered orally for at least one week preoperatively and postoperatively
Number of subjects: 129
Study: 10488954

Group type: EXPERIMENTAL
Intervention: Sitostanol ester margarine
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (home diet)
Number of subjects: 151
Study: 8942421

Group type: COMPARATOR
Intervention: Oat bran diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-amylose starch diet
Number of subjects: 23
Study: 1757595

Group type: EXPERIMENTAL
Intervention: Constant stimulus condition (same audiotape presented for three weeks)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Variable stimulus condition (different audiotape presented each session)
Number of subjects: 5
Study: 7051247

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31834418

Group type: EXPERIMENTAL
Intervention: Modified arthroscopic approach (group B)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Open tibial inlay technique (group A)
Number of subjects: 11
Study: 30664882

Group type: EXPERIMENTAL
Intervention: Intravenous scorpion antivenom
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular scorpion antivenom
Number of subjects: 100
Study: 28433371

Group type: EXPERIMENTAL
Intervention: PGD‐A group (preimplantation genetic diagnosis for aneuploidy screening)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PGD‐A group
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (blastocyst transfer without PGD‐A)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 28095373

Group type: EXPERIMENTAL
Intervention: Field MAL‐PDT (FT side)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lesion‐by‐lesion MAL‐PDT (LT side)
Number of subjects: 0
Study: 26474438

Group type: EXPERIMENTAL
Intervention: Cognitively demanding physical education lesson consisting of different coordinative exercises
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal sedentary school lesson
Number of subjects: 90
Study: 23203544

Group type: EXPERIMENTAL
Intervention: Micro-pump (MP) administration of epirubicin for 48 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous drip (ID) administration of epirubicin for 1 hour
Number of subjects: 11
Study: 20064862

Group type: EXPERIMENTAL
Intervention: Cough trick technique (single 'warm-up' cough followed by a second cough coinciding with needle puncture)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (standard immunization procedure without cough trick)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Satisfaction measure for older participants and nurses
Number of subjects: 68
Study: 17510682

Group type: EXPERIMENTAL
Intervention: n‐3 FA supplementation alone (FO, n=10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: n‐3 FA supplementation plus exercise training (FO+ExTr, n=12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 22
Study: 15789189

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11870119

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10076899

Group type: EXPERIMENTAL
Intervention: Theta power during haptic exploration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theta power
Number of subjects: 0
Study: 7671838

Group type: EXPERIMENTAL
Intervention: Molded heterograft tympanic membrane
Number of subjects: 25

Group type: COMPARATOR
Intervention: Autograft (implied as control)
Number of subjects: 25
Study: 2188217

Group type: EXPERIMENTAL
Intervention: Comprehensive discharge planning protocol implemented by a gerontological nurse specialist
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospital's general discharge planning procedure
Number of subjects: 0
Study: 6652009

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (non-pregnant patients)
Number of subjects: 60
Study: 31736025

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 20 ml 0.25 % bupivacaine (10 ml for each level) preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 28941314

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27100333

Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in various conditions (coffee vs energy drink, different rates of consumption, and temperature)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in coffee
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine (dose = 160 mg) administered in energy drink
Number of subjects: 24
Study: 25145375

Group type: EXPERIMENTAL
Intervention: Alternative tobacco products (ATPs) including e-cigarettes, little cigars/cigarillos, hookah, other smokeless tobacco products, chewing tobacco/moist snuff
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Planning to quit smoking in the next 30 days
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Lifetime e-cigarette users
Number of subjects: 292
Study: 21659626

Group type: EXPERIMENTAL
Intervention: Aliskiren/HCT 300/25 mg SPC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free combination of aliskiren and HCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aliskiren (when administered with HCT)
Number of subjects: 0
Study: 19560111

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 61

Group type: COMPARATOR
Intervention: mepivacaine
Number of subjects: 61
Study: 20688256

Group type: EXPERIMENTAL
Intervention: AG5
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 16142255

Group type: EXPERIMENTAL
Intervention: Bone marrow scintigraphy (BMS) with 99mTc‐sulphur‐colloid
Number of subjects: 47

Group type: COMPARATOR
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 47
Study: 12147533

Group type: EXPERIMENTAL
Intervention: Post-PTCA VBT with Sr90
Number of subjects: 30
Study: 9663913

Group type: EXPERIMENTAL
Intervention: Automated oscillometric device
Number of subjects: 400

Group type: COMPARATOR
Intervention: Aneroid sphygmomanometer
Number of subjects: 400
Study: 7923656

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231
Study: 3044181

Group type: EXPERIMENTAL
Intervention: Nalbuphine (20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Piritramide (15 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 60
Study: 30088425

Group type: EXPERIMENTAL
Intervention: NGAL test result provided to doctors for risk assessment
Number of subjects: 0
Study: 26820419

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (off MPH)
Number of subjects: 24
Study: 24150547

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (Propofol and Sevoflurane)
Number of subjects: 30
Study: 22451320

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Social Interaction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 120

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 120
Study: 20833444

Group type: EXPERIMENTAL
Intervention: Etanercept (intermittent therapy)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Etanercept (blinded)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (blinded)
Number of subjects: 138
Study: 18500561

Group type: EXPERIMENTAL
Intervention: Optimized tablet (M-7) containing chitosan and hydroxypropyl methylcellulose phthalate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed tablet
Number of subjects: 0
Study: 15705006

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual Clinical Care (UC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT) (post hoc analysis)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual Clinical Care (UC) (post hoc analysis)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Behavioral Treatment (BT) (week 14)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual Clinical Care (UC) (week 14)
Number of subjects: 72
Study: 12852711

Group type: EXPERIMENTAL
Intervention: 10 g PLT 3514 emulsion (0.75 g GLA + 0.5 g EPA)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 15 g PLT 3514 emulsion (1.13 g GLA + 0.75 g EPA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (olive oil) emulsion
Number of subjects: 43
Study: 10494189

Group type: EXPERIMENTAL
Intervention: First line treatment for Hodgkin's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with autologous stem cell support
Number of subjects: 0
Study: 8975400

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg orally three times a day for seven days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 80
Study: 1686733

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (sCT) 100 MRC units, im
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 6140261

Group type: EXPERIMENTAL
Intervention: Lorazepam (1 mg and 2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam (5 mg and 10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clorazepate (7.5 mg and 15 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31345971

Group type: EXPERIMENTAL
Intervention: HBCPs' programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HBCPs' programme + mobile health application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 30261125

Group type: EXPERIMENTAL
Intervention: Low-amount, low-intensity exercise (180 kcal/session for women, 300 kcal/session for men at 50% VO2 peak)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: High-amount, low-intensity exercise (HALI; 360 kcal/session for women, 600 kcal/session for men at 50% VO2 peak)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: High-amount, high-intensity exercise (HAHI; 360 kcal/session for women, 600 kcal/session for men at 75% VO2 peak)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 26372680

Group type: COMPARATOR
Intervention: Serum chitotriosidase and YKL-40 levels in patients with asthma and COPD
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Genotype and age effects on YKL-40 and chitotriosidase activity
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Acute exacerbations, allergen-induced airway obstruction, and corticosteroid treatment
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Allergen inhalation effects on blood and sputum YKL-40 levels
Number of subjects: 233
Study: 24779524

Group type: EXPERIMENTAL
Intervention: Electronic health record-based transitional care intervention
Number of subjects: 3671

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3671
Study: 22313688

Group type: EXPERIMENTAL
Intervention: Triumph(®) triclosan eluting stent
Number of subjects: 20

Group type: COMPARATOR
Intervention: Percuflex Plus(®) non-eluting stent (control)
Number of subjects: 20
Study: 21149331

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 389

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Age (10 years increase)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Race (African Americans vs Caucasians and Hispanics)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Location (Rectum vs Right Colon)
Number of subjects: 389
Study: 18058479

Group type: EXPERIMENTAL
Intervention: Amlodipine maleate 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amlodipine besylate 10 mg (Norvasc)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amlodipine maleate and besylate (both)
Number of subjects: 24
Study: 16118338

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (E2) supplementation (2 mg/d for 8 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 11222360

Group type: EXPERIMENTAL
Intervention: Chronic graft-versus-host disease (GVHD) management strategies
Number of subjects: 0
Study: 9641502

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7584302

Group type: EXPERIMENTAL
Intervention: Children who participated in the event three times in a spatial condition.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Children who participated in the event one time in a spatial condition.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Children who participated in the event one or three times in a nonspatial condition.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (same-aged controls).
Number of subjects: 37
Study: 2680790

Group type: EXPERIMENTAL
Intervention: 3-drug therapy (Adriablastine, Cisplatin, Cyclophosphamide)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Two-drug chemotherapy without Cisplatin
Number of subjects: 48
Study: 988458

Group type: EXPERIMENTAL
Intervention: Desoximethasone 0.25%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.10%
Number of subjects: 26
Study: 31155896

Group type: EXPERIMENTAL
Intervention: Anal fistulotomy and marsupialisation of the edges of the laid open track
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anal fistulotomy
Number of subjects: 60
Study: 29296598

Group type: EXPERIMENTAL
Intervention: Individual counseling program by a midwife during three sessions
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Individual counseling program by a midwife
Number of subjects: 90